Pharmaco-EEG profile of levoprotiline: second example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs.

@article{Wm1991PharmacoEEGPO,
  title={Pharmaco-EEG profile of levoprotiline: second example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs.},
  author={Herrmann Wm and E. Sch{\"a}rer and G. Wendt and A. Delini-Stula},
  journal={Pharmacopsychiatry},
  year={1991},
  volume={24},
  pages={214-224}
}
This publication forms the third part of a critical evaluation of pharmaco-EEG applications as an instrument for assessing the profile of action of psychoactive drugs based on the trial results of three new psychoactive test substances: savoxepine, levoprotiline and maroxepine. After the presentation, in Parts I (savoxepine) and II (levoprotiline), of trial substances for which compatible results were obtained in the pharmaco-EEG model and in the clinical studies, a case with discrepant and… Expand
EEG, MAO‐A inhibition, pharmacokinetics and safety of befloxatone in the elderly
Befloxatone is a new reversible and selective MAO‐A inhibitor. The present study aimed to assess the pharmacodynamics (EEG profile and MAO‐A inhibition using plasma levels of DHPG), pharmacokineticsExpand
Pharmaco-EEG Studies in Animals: A History-Based Introduction to Contemporary Translational Applications
TLDR
General statements about the usefulness of EEG as a biomarker to demonstrate the translatability of p-EEG effects should be made with caution, however, because they depend on the particular EEG or sleep parameter that is being studied. Expand
Biomarkers for the effects of antipsychotic drugs in healthy volunteers.
TLDR
Subjective and objective measures of alertness, and of visual-visuomotor-auditory and motor skills were most sensitive to antipsychotics, although over half of all the studies failed to show statistically significant differences from placebo. Expand
Contrasting EEG profiles elicited by antipsychotic agents in the prefrontal cortex of the conscious rat: antagonism of the effects of clozapine by modafinil
TLDR
Different pharmacological classes of antipsychotic show synchronization or desynchronization of the EEG in the prefrontal cortex, with the benzamides showing a distinctive spectrum. Expand
Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission
TLDR
In conclusion, pharmacological modulation of dopaminergic and noradrenergic transmission may result in consistent EEG changes: decreased dopamergic or nor adrenoceptor activity induces an increase of EEG spectral power; while increased dopaminerential or norad Renergic activity decreases EEG spectralPower. Expand
The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder.
TLDR
Use of QEEG technology to predict antidepressant response in major depression may mean that more patients will achieve response and remission with less of the trial-and-error approach that currently accompanies antidepressant treatment. Expand
Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study.
TLDR
The results suggest that decrease in prefrontal cordance may indicate early changes of prefrontal activity in responders to antidepressants and QEEG Cordance may become a useful tool in the prediction of response to antidepressants. Expand
Early Changes in Prefrontal Activity Characterize Clinical Responders to Antidepressants
TLDR
Findings implicate the prefrontal region in mediating response to antidepressant medications and a new measure, cordance, for detecting regional changes associated with treatment response may have clinical applicability as a leading indicator of individual response. Expand
Antipsychotic medication for early episode schizophrenia.
TLDR
The preliminary pattern of evidence suggests that people with early episode schizophrenia treated with typical antipsychotic medications are less likely to leave the study early than those treated with placebo, and there is very little useable data in the few studies meeting inclusion criteria. Expand
Chlorpromazine versus placebo for schizophrenia.
TLDR
It is found chlorpromazine provided a global improvement in a person's symptoms and functioning and reduces relapse over the short and medium term and in the long term. Expand
...
1
2
...